Equities research analysts expect Illumina, Inc. (NASDAQ:ILMN) to report sales of $860.57 million for the current fiscal quarter, according to Zacks Investment Research. Six analysts have made estimates for Illumina’s earnings, with the highest sales estimate coming in at $870.00 million and the lowest estimate coming in at $855.90 million. Illumina reported sales of $778.00 million during the same quarter last year, which would suggest a positive year over year growth rate of 10.6%. The business is expected to issue its next quarterly earnings results on Tuesday, January 29th.

On average, analysts expect that Illumina will report full-year sales of $3.33 billion for the current fiscal year, with estimates ranging from $3.32 billion to $3.35 billion. For the next fiscal year, analysts anticipate that the firm will report sales of $3.80 billion, with estimates ranging from $3.70 billion to $3.97 billion. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that follow Illumina.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, October 23rd. The life sciences company reported $1.52 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.26 by $0.26. The firm had revenue of $853.00 million during the quarter, compared to analyst estimates of $825.65 million. Illumina had a net margin of 21.09% and a return on equity of 27.10%. The company’s revenue for the quarter was up 19.5% on a year-over-year basis. During the same quarter last year, the business posted $1.11 EPS.

Several equities research analysts have commented on ILMN shares. ValuEngine lowered shares of Illumina from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 11th. Barclays increased their price objective on shares of Illumina from $350.00 to $370.00 and gave the company an “overweight” rating in a research note on Wednesday, October 24th. BidaskClub upgraded shares of Illumina from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 1st. Argus set a $372.00 price objective on shares of Illumina and gave the company a “buy” rating in a research note on Friday, August 10th. Finally, Cowen increased their price objective on shares of Illumina from $315.00 to $400.00 and gave the company a “positive” rating in a research note on Thursday, September 6th. Six equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $330.94.

In other news, SVP Charles Dadswell sold 566 shares of the firm’s stock in a transaction that occurred on Monday, December 3rd. The shares were sold at an average price of $343.57, for a total transaction of $194,460.62. Following the completion of the sale, the senior vice president now owns 5,606 shares in the company, valued at approximately $1,926,053.42. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Francis A. Desouza sold 2,100 shares of the firm’s stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $369.61, for a total transaction of $776,181.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 71,428 shares of company stock valued at $23,533,478. 0.54% of the stock is currently owned by company insiders.

Several hedge funds have recently modified their holdings of the company. Belpointe Asset Management LLC purchased a new position in Illumina in the 3rd quarter valued at approximately $155,000. Vanguard Group Inc. grew its stake in Illumina by 1.8% in the 3rd quarter. Vanguard Group Inc. now owns 10,833,784 shares of the life sciences company’s stock valued at $3,976,649,000 after buying an additional 188,516 shares in the last quarter. Legal & General Group Plc grew its stake in Illumina by 6.8% in the 3rd quarter. Legal & General Group Plc now owns 657,774 shares of the life sciences company’s stock valued at $241,442,000 after buying an additional 41,978 shares in the last quarter. Kepos Capital LP grew its stake in Illumina by 394.5% in the 3rd quarter. Kepos Capital LP now owns 12,037 shares of the life sciences company’s stock valued at $4,418,000 after buying an additional 9,603 shares in the last quarter. Finally, Financial Enhancement Group LLC purchased a new position in Illumina in the 3rd quarter valued at approximately $400,000. Institutional investors own 88.91% of the company’s stock.

NASDAQ:ILMN traded up $0.11 on Monday, hitting $334.32. The stock had a trading volume of 1,478,902 shares, compared to its average volume of 944,704. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.24 and a current ratio of 2.46. The firm has a market cap of $49.13 billion, a price-to-earnings ratio of 83.58, a price-to-earnings-growth ratio of 2.48 and a beta of 1.09. Illumina has a 1 year low of $207.51 and a 1 year high of $372.61.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Recommended Story: Cost of equity and a company’s balance sheet

Get a free copy of the Zacks research report on Illumina (ILMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.